You are here

Alnylam

Bio Roundup: Nationwide’s Rise, a Surgeon’s Quest, CRISPR USA & More

Bio Roundup: Nationwide’s Rise, a Surgeon’s Quest, CRISPR USA & More

Xconomy

Adverum Biotechnologies

Blackstone Life Sciences

Flag link:

Alnylam's givosiran reduces mean porphyria attacks by 74% in Phase III

Alnylam's givosiran reduces mean porphyria attacks by 74% in Phase III

BioCentury

acute hepatic porphyria

Flag link:

Regeneron, Alnylam spell out a research alliance that could run beyond a decade, with billions built in for success

Regeneron, Alnylam spell out a research alliance that could run beyond a decade, with billions built in for success

Endpoints

Flag link:

Alnylam Gets $800M From Regeneron to Bring RNAi to Eye, Brain Diseases

Alnylam Gets $800M From Regeneron to Bring RNAi to Eye, Brain Diseases

Xconomy

Flag link:

2 Biotechs With Big Dates in April

2 Biotechs With Big Dates in April

Motley Fool

Intercept Pharmaceuticals

Flag link:

After landing a historic FDA OK, Alnylam chief John Maraganore scores a big raise

After landing a historic FDA OK, Alnylam chief John Maraganore scores a big raise

Endpoints

John Maraganore

Flag link:

Data in Hand, Alnylam To Seek OK For Second RNAi Drug

Data in Hand, Alnylam To Seek OK For Second RNAi Drug

Xconomy

acute hepatic porphyria

Flag link:

Upcoming events – Fibrogen and Alnylam look to broaden their horizons

Upcoming events – Fibrogen and Alnylam look to broaden their horizons

EP Vantage

Duchenne Muscular Dystrophy

Flag link:

Alnylam Pharmaceuticals Is Launched and Ready for More

Alnylam Pharmaceuticals Is Launched and Ready for More

Motley Fool

ATTR amyloidosis

Flag link:

Is the Smoldering NASH Market Ready to Burst Into Flames?

Is the Smoldering NASH Market Ready to Burst Into Flames?

BioSpace

Gilead Sciences

Bristol-Myers Squibb

Intercept Pharmaceuticals

Flag link:

Alnylam CEO talks politics, gene therapy and not becoming Pfizer

Alnylam CEO talks politics, gene therapy and not becoming Pfizer

BioPharma Dive

John Maraganore

Flag link:

5 Top Drug/Biotech Merger & Acquisition Targets for 2019

5 Top Drug/Biotech Merger & Acquisition Targets for 2019

Yahoo/Zacks.com

Vertex Pharmaceuticals

Flag link:

Alnylam's Onpattro sales look 'disappointing' in early days of RNAi launch: analyst

Alnylam's Onpattro sales look 'disappointing' in early days of RNAi launch: analyst

Fierce Pharma

hATTR amyloidosis

Flag link:

Alnylam shares drop 1.8% on new FDA approval strategy for rare disease drug

Alnylam shares drop 1.8% on new FDA approval strategy for rare disease drug

Marketwatch

acute hepatic porphyria

Flag link:

FDA clears rare disease therapy from Akcea, Ionis

FDA clears rare disease therapy from Akcea, Ionis

Biopharma Dive

Ionis Pharmaceuticals

hATTR amyloidosis

Flag link:

Alnylam seeks MHRA approval to start ALN-AAT02 phase 1/2 trial

Alnylam seeks MHRA approval to start ALN-AAT02 phase 1/2 trial

Pharmaceutical Business Review

Flag link:

Alnylam Submits NDA in Japan for Onpattro for Hereditary ATTR Amyloidosis

Alnylam Submits NDA in Japan for Onpattro for Hereditary ATTR Amyloidosis

CP Wire

hATTR amyloidosis

Flag link:

Alnylam, with positive data on second gene-silencing drug, plans filing to FDA

Alnylam, with positive data on second gene-silencing drug, plans filing to FDA

Stat

acute hepatic porphyrias

Flag link:

Alnylam Announces Encouraging Exploratory Cardiac Endpoint Data For Patisiran in hATTR Amyloidosis

Alnylam Announces Encouraging Exploratory Cardiac Endpoint Data For Patisiran in hATTR Amyloidosis

CP Wire

hATTR amyloidosis

Flag link:

Alnylam Announces Encouraging Exploratory Cardiac Endpoint Data For Patisiran in hATTR Amyloidosis

hATTR amyloidosis

Flag link:

Pages